FLOSEAL Hemostatic Matrix + Standard of care
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
82
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Knee Replacement Surgery
Conditions
Knee Replacement Surgery, Osteoarthritis
Trial Timeline
Sep 1, 2011 โ Jan 1, 2013
NCT ID
NCT01410240About FLOSEAL Hemostatic Matrix + Standard of care
FLOSEAL Hemostatic Matrix + Standard of care is a approved stage product being developed by Baxter for Knee Replacement Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT01410240. Target conditions include Knee Replacement Surgery, Osteoarthritis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01410240 | Approved | Completed |
Competing Products
20 competing products in Knee Replacement Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2828360 + Placebo | Eli Lilly | Phase 2 | 52 |
| UBX0101 or placebo | Unity Biotechnology | Pre-clinical | 15 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |
| UBX0101 | Unity Biotechnology | Phase 2 | 44 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |
| YH23537 + Celecoxib + YH23537 placebo | Yuhan | Phase 2 | 52 |
| YM150 + Warfarin | Astellas Pharma | Phase 2 | 52 |
| ASP7962 + Naproxen + Placebo | Astellas Pharma | Phase 2 | 52 |
| Capsaicin Topical Solution | Astellas Pharma | Approved | 85 |
| CGS-200-1 + CGS-200-5 + CGS-200 Vehicle | Astellas Pharma | Phase 2 | 52 |
| MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Duloxetine + Placebo | Shionogi | Phase 3 | 77 |
| Duloxetine | Shionogi | Phase 3 | 77 |
| V120083 + Naproxen + Placebo | Shionogi | Phase 2 | 52 |
| ONO-4474 + Placebo matching ONO-4474 | Ono Pharmaceutical | Phase 2 | 52 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine (DLX) + Placebo (PLA) | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + LY545694 49 mg + LY545694 105 mg | Eli Lilly | Phase 2 | 52 |
| LY517717 + enoxaparin | Eli Lilly | Phase 2 | 52 |